Last reviewed · How we verify
RB
Rivaroxaban is an anticoagulant that works by inhibiting Factor Xa.
Rivaroxaban is an anticoagulant that works by inhibiting Factor Xa. Used for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | RB |
|---|---|
| Sponsor | Kim, Seok Jin |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban is a direct Factor Xa inhibitor, which means it directly blocks the activity of Factor Xa, a key enzyme in the coagulation cascade. This leads to a reduction in thrombin formation and subsequent clot formation.
Approved indications
- Deep vein thrombosis
- Pulmonary embolism
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Gastrointestinal bleeding
- Hemorrhage
- Anemia
- Thrombocytopenia
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Abemaciclib in Newly Diagnosed Meningioma Patients (PHASE2)
- Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome (PHASE2)
- Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients (EARLY_PHASE1)
- Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer (PHASE2)
- NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings (PHASE4)
- A Comparative Study Between Combination of Propofol and Dexmedetomidine Versus Propofol Alone in Anesthesia for Rigid Bronchoscopy by Using the Patient State Index Monitor (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RB CI brief — competitive landscape report
- RB updates RSS · CI watch RSS
- Kim, Seok Jin portfolio CI